Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (The British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158–1166.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat. 2020;1–9. DOI:10.1080/09546634.2020.1832187.
   Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Maintenance of response through up to 4 years of continuous Guselkumab treatment of psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020;21(6):881–890.
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146–1159.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827–834.
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat. 2014;25(1):54–56.
   PubMed Web of Science ®Google Scholar
• Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol. 2012;166(1):189–195.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2009;160(1):162–169.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2010;163(4):859–862.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Bianchi L, et al. What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice. Dermatology. 2014;229(4):324–332.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of Guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year Real-Life Study. J Clin Med. 2020;9(7):2170.
   PubMed Web of Science ®Google Scholar
• Snast I, Sherman S, Holzman R, et al. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964.
   PubMed Web of Science ®Google Scholar
• Schwensen JFB, Nielsen VW, Nissen CV, et al. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol. 2021;35(5):e341–e3.
   PubMed Web of Science ®Google Scholar
• Malara G, Trifiro C, Bartolotta A, et al. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021;25(1):406–412.
   PubMed Web of Science ®Google Scholar
• Chan Y, Tong BSB, Ngan PY, et al. Effectiveness of IL-23 inhibitor Guselkumab in real-world Chinese patients with psoriasis during a 20-week period. Psoriasis (Auckl). 2021;11:53–58.
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Cinelli E, et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2022;33(2):1074–1078.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–5. doi:10.1080/09546634.2022.2036674.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Brau B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–1862.
   PubMed Web of Science ®Google Scholar
• Hung YT, Lin YJ, Chiu HY, et al. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv Chronic Dis. 2021;12:20406223211046685.
   Web of Science ®Google Scholar
• Del Alcazar E, Lopez-Ferrer A, Martinez-Domenech A, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2021;35(2) :e15231.
   Web of Science ®Google Scholar
• Bardazzi F, Viviani F, Merli Y, et al. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opin Biol Ther. 2022;1–6. DOI:10.1080/14712598.2022.2064216.
   PubMed Web of Science ®Google Scholar
• Seidl U, Pinter A, Wilsmann-Theis D, et al. Absolute psoriasis area and severity index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. Dermatol Ther. 2022;35(1):e15193.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Reich K, Foley P, et al. Improvement in patient-reported outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in moderate-to-severe plaque psoriasis: results from the Phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol. 2019;20(1):155–164.
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, et al. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2):e14798.
   PubMed Web of Science ®Google Scholar